Search

Your search keyword '"Paolo Caraceni"' showing total 33 results
Start Over Author "Paolo Caraceni" Journal digestive and liver disease
33 results on '"Paolo Caraceni"'

1. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

Author

Benedetta Stefanini, Laura Bucci, Valentina Santi, Nicola Reggidori, Davide Rampoldi, Lorenzo Lani, Alessandro Granito, Angelo Sangiovanni, Giuseppe Cabibbo, Fabio Farinati, Claudia Campani, Francesco Giuseppe Foschi, Gianluca Svegliati-Baroni, Giovanni Raimondo, Antonio Gasbarrini, Andrea Mega, Elisabetta Biasini, Rodolfo Sacco, Filomena Morisco, Eugenio Caturelli, Gianpaolo Vidili, Francesco Azzaroli, Edoardo G. Giannini, Gian Ludovico Rapaccini, Maurizia Rossana Brunetto, Alberto Masotto, Gerardo Nardone, Mariella Di Marco, Donatella Magalotti, Franco Trevisani, Maurizio Biselli, Paolo Caraceni, Annagiulia Gramenzi, Francesco Tovoli, Luca Muratori, Francesca Benevento, Gloria Allegrini, Calogero Cammà, Ciro Celsa, Paolo Giuffrida, Caterina Stornello, Mauro Grova, Carmelo Marco Giacchetto, Gabriele Rancatore, Maria Vittoria Grassini, Valentina Adotti, Stefano Gitto, Fabio Marra, Martina Rosi, Vittoria Bevilacqua, Alberto Borghi, Andrea Casadei Gardini, Fabio Conti, Anna Chiara Dall'Aglio, Giorgio Ercolani, Federica Mirici, Nicoletta de Matthaeis, Francesca Romana Ponziani, Gabriele Missale, Andrea Olivani, Maria Guarino, Valentina Cossiga, Mario Capasso, Ester Marina Cela, Antonio Facciorusso, Valentina Lauria, Giorgia Ghittoni, Giorgio Pelecca, Fabrizio Chegai, Fabio Coratella, Mariano Ortenzi, Serena Dell'Isola, Maria Stella Franzè, Carlo Saitta, Assunta Sauchella, Elton Dajti, Federico Ravaioli, Giulia Pieri, Maria Corina Plaz Torres, Filippo Oliveri, Gabriele Ricco, Veronica Romagnoli, Alessandro Inno, Fabiana Marchetti, Pietro Coccoli, Antonio Malerba, Alberta Cappelli, Rita Golfieri, Cristina Mosconi, null Matteo Renzulli, Stefanini, B., Bucci, L., Santi, V., Reggidori, N., Rampoldi, D., Lani, L., Granito, A., Sangiovanni, A., Cabibbo, G., Farinati, F., Campani, C., Foschi, F. G., Svegliati-Baroni, G., Raimondo, G., Gasbarrini, A., Mega, A., Biasini, E., Sacco, R., Morisco, F., Caturelli, E., Vidili, G., Azzaroli, F., Giannini, E. G., Rapaccini, G. L., Brunetto, M. R., Masotto, A., Nardone, G., Di Marco, M., Magalotti, D., Trevisani, F., Biselli, M., Caraceni, P., Gramenzi, A., Tovoli, F., Muratori, L., Benevento, F., Allegrini, G., Camma, C., Celsa, C., Giuffrida, P., Stornello, C., Grova, M., Giacchetto, C. M., Rancatore, G., Grassini, M. V., Adotti, V., Gitto, S., Marra, F., Rosi, M., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, F., Dall'Aglio, A. C., Ercolani, G., Mirici, F., de Matthaeis, N., Ponziani, F. R., Missale, G., Olivani, A., Guarino, M., Cossiga, V., Capasso, M., Cela, E. M., Facciorusso, A., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Dell'Isola, S., Franze, M. S., Saitta, C., Sauchella, A., Dajti, E., Ravaioli, F., Pieri, G., Torres, M. C. P., Oliveri, F., Ricco, G., Romagnoli, V., Inno, A., Marchetti, F., Coccoli, P., Malerba, A., Cappelli, A., Golfieri, R., Mosconi, C., Matteo, Renzulli, Stefanini, Benedetta, Bucci, Laura, Santi, Valentina, Reggidori, Nicola, Rampoldi, Davide, Lani, Lorenzo, Granito, Alessandro, Sangiovanni, Angelo, Cabibbo, Giuseppe, Farinati, Fabio, Campani, Claudia, Foschi, Francesco Giuseppe, Svegliati-Baroni, Gianluca, Raimondo, Giovanni, Gasbarrini, Antonio, Mega, Andrea, Biasini, Elisabetta, Sacco, Rodolfo, Morisco, Filomena, Caturelli, Eugenio, Vidili, Gianpaolo, Azzaroli, Francesco, Giannini, Edoardo G, Rapaccini, Gian Ludovico, Brunetto, Maurizia Rossana, Masotto, Alberto, Nardone, Gerardo, Di Marco, Mariella, Magalotti, Donatella, and Trevisani, Franco

Subjects
Atezolizumab-bevacizumab, Clinical Trials as Topic, Antineoplastic Combined Chemotherapy Protocol, Carcinoma, Hepatocellular, Systemic therapy, Hepatology, Hepatocellular carcinoma, Tirosin-kinase inhibitor, Liver Neoplasms, Gastroenterology, Bevacizumab, Feasibility Studie, Tyrosine, Human
Abstract

Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, be-coming the standard of care of systemic therapy.Aim: This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Methods: Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.Results: 422 (29%) patients were qualified for atezolizumab-bevacizumab therapy. The main exclusion causes were Child-Pugh class and Performance Status. Adopting the more permissive inclusion criteria of SHARP trial, 535 patients became eligible. The median overall survival of tyrosine-kinase inhibitors patients was 14.9 months, longer in eligible patients than in their counterpart due to better baseline liver function and oncological features.Conclusion: Real-world data indicate that less than one-third of hepatocellular carcinoma patients treated with tyrosine-kinase inhibitors are potentially eligible to atezolizumab-bevacizumab according to the reg-istration trial criteria. These patients have a longer survival than the non-eligible ones. If the selection criteria of atezolizumab-bevacizumab trial are maintained in clinical practice, tyrosine-kinase inhibitors will remain the most used systemic therapy for hepatocellular carcinoma patients.(c) 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Published
2022

2. Liver transplantation in patients with ACLF. Preliminary experience of 6 Italian centres

Author

Stefano Fagiuoli, C. Morelli, Salvatore Piano, Luca S. Belli, Paolo Caraceni, Silvia Martini, Riccardo Volpes, P. Angeli, C. Ieri, Chiara Mazzarelli, Giovanni Perricone, Ioannis Petridis, and S. Ottobrelli

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine.medical_treatment, Gastroenterology, Medicine, In patient, Liver transplantation, business
Published
2020

3. Effective albumin concentration and albumin function improve after long-term albumin therapy in patients with decompensated cirrhosis

Author

Paolo Caraceni, F.G. Foschi, Maurizio Baldassarre, Katja Waterstradt, Giacomo Zaccherini, Francesco Vizzutti, Manuel Tufoni, Daniela Campion, Silvia Nardelli, Martina Gagliardi, Agnese Antognoli, Chiara Donadei, Sara Massironi, Alessandro Federico, Aldo Airoldi, Marina Naldi, Filomena Morisco, and Maria Martha Bernardi

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, Albumin, Medicine, In patient, business, Decompensated cirrhosis
Published
2020

4. Subtle changes of c-reactive protein and serum creatinine during the index hospitalization predict early readmission in patients with decompensated cirrhosis

Author

Paolo Caraceni, G. Iannone, Simona Leoni, Maurizio Baldassarre, E. Basigli, Giacomo Zaccherini, Agnese Antognoli, Manuel Tufoni, Sonia Berardi, Mariarosa Tamè, L. Marconi, D. Pratelli, P. Viale, Franco Trevisani, Michele Bartoletti, and Marco Domenicali

Subjects
medicine.medical_specialty, Creatinine, Hepatology, biology, business.industry, C-reactive protein, Gastroenterology, Decompensated cirrhosis, chemistry.chemical_compound, chemistry, Internal medicine, medicine, biology.protein, In patient, business, Index hospitalization
Published
2020

5. Epidemiology, predictors and outcomes of multi drug resistant (MDR) bacterial infections in patients with cirrhosis across the world. Final results of the 'Global study'

Author

Nicolas M. Intagliata, Salvatore Piano, Luis Colombato, Xavier Verhelst, M. Marino, Carlo Alessandria, Javier Fernández, Julio Vorobioff, Juan Pablo Roblero, Adrián Gadano, K.R. Bhamidimarri, Alexander L. Gerbes, S.E. Kim, L. Elkrief, S.K. Sarin, Aleksander Krag, Shivaram Prasad Singh, Paolo Caraceni, M. Maevskaya, J.-S. Hwang, Laurentius A. Lesmana, Liane Rabinowich, Eduardo Fassio, E.C. Soares, Virendra Singh, Florence Wong, C. Toledo, Sang Gyune Kim, R. Ribeiro Barea, Thomas D. Boyer, Manuela Merli, H.S. Kim, Doo-Man Kim, Paolo Angeli, Rakhi Maiwall, F. Durand, Victor Vargas, and Sebastián Marciano

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Gastroenterology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Epidemiology, medicine, Multi drug resistant, 030211 gastroenterology & hepatology, In patient, business
Published
2018

6. The residual native albumin predicts albumin dysfunction and outcomes in hospitalized cirrhotic patients with acute decompensation or acute-on-chronic liver failure

Author

G. Iannone, Maurizio Baldassarre, M. Bartolini, Franco Trevisani, D. Pratelli, Paolo Caraceni, Giacomo Zaccherini, Marco Domenicali, Katja Waterstradt, Marina Naldi, Maria Martha Bernardi, Michele Bartoletti, Agnese Antognoli, Maristella Laggetta, and Martina Gagliardi

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, Albumin, medicine, Decompensation, Acute on chronic liver failure, business
Published
2019

7. Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment

Author

F.G. Foschi, V. Di Marco, Gianluca Svegliati-Baroni, Manuel Tufoni, Annalisa Tortora, Paolo Caraceni, Roberto Giulio Romanelli, Maria Martha Bernardi, Giacomo Zaccherini, Aldo Airoldi, Sergio Neri, Salvatore Piano, Silvia Nardelli, L. Simone, F. Levantesi, Raffaele Cozzolongo, Pierluigi Toniutto, Paolo Angeli, Chiara Elia, C. Alessandria, A. Roncadori, Maurizio Baldassarre, Oliviero Riggio, Stefano Fagiuoli, Filomena Morisco, Vincenzo Sangiovanni, and R. De Marco

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, biology, business.industry, Gastroenterology, Serum albumin, Albumin, medicine.disease, Internal medicine, Ascites, medicine, biology.protein, In patient, medicine.symptom, business
Published
2019

8. Predictors of nosocomial acute-on-chronic liver failure for the risk stratification of patients with cirrhosis admitted to hospital with acute decompensation

Author

G. Iannone, Lucia Napoli, P. Viale, Giacomo Zaccherini, Marco Domenicali, Maria Martha Bernardi, Sonia Berardi, A. Fabbri, Michele Bartoletti, Antonio Siniscalchi, Maurizio Baldassarre, Agnese Antognoli, Franco Trevisani, Paolo Caraceni, L. Marconi, and Mariarosa Tamè

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Internal medicine, Risk stratification, Gastroenterology, medicine, Decompensation, Acute on chronic liver failure, medicine.disease, business
Published
2019

9. Bacterial infections with and without acute-on-chronic liver failure in patients with cirrhosis and acute decompensation: Risk factors and outcome

Author

R. Lewis, Marco Domenicali, Manuel Tufoni, Paolo Caraceni, Maddalena Giannella, Sonia Berardi, F.M. Pavarin, Maurizio Baldassarre, Michele Bartoletti, Maria Martha Bernardi, P. Viale, Matteo Rinaldi, Giacomo Zaccherini, F. Angela, Lucia Napoli, Franco Trevisani, and Mariarosa Tamè

Subjects
0301 basic medicine, medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Gastroenterology, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Internal medicine, medicine, 030211 gastroenterology & hepatology, Acute on chronic liver failure, In patient, Decompensation, business
Published
2018

10. Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury

Author

Lucia Catani, S. Talarico, Marco Domenicali, Roberto M. Lemoli, Mauro Bernardi, Anna Maria Pertosa, A. Principe, Miriam Fogli, Franco Trevisani, Ferdinando Giannone, Paolo Caraceni, Michele Baccarani, Caraceni P, Giannone F, Catani L, Talarico S, Pertosa AM, Domenicali M, Fogli M, Principe A, Trevisani F, Baccarani M, Bernardi M, and Lemoli RM.

Subjects
Male, medicine.medical_treatment, G-CSF, Granulocyte, Pharmacology, Rats, Sprague-Dawley, Leukocyte Count, Colony-Stimulating Factors, medicine, Animals, Carbon Tetrachloride, Image Cytometry, Colony-forming unit, Liver injury, Hepatology, business.industry, Gastroenterology, Liver Failure, Acute, medicine.disease, Immunohistochemistry, Recombinant Proteins, Liver regeneration, Liver Regeneration, Rats, Granulocyte colony-stimulating factor, Disease Models, Animal, Haematopoiesis, Treatment Outcome, medicine.anatomical_structure, Immunology, Bone marrow, Hepatectomy, business, ACUTE LIVER INJURY
Abstract

Background/aim Controversial experimental observations suggest that granulocyte colony stimulating-factor may promote hepatic regeneration after hepatectomy and chemical injury either by directly stimulating adult liver cells or facilitating the mobilization of bone marrow cells and their homing to the liver. We investigated whether different schedules of granulocyte colony stimulating-factor administration protect against experimental acute liver injury. Methods Acute liver injury was induced in Sprague-Dawley fed rats by injecting a single intraperitoneal dose of carbon tetrachloride. Recombinant human granulocyte colony stimulating-factor or vehicle was given daily after intoxication (4 days) or before (7 days) and after carbon tetrachloride administration. Liver injury and regeneration were assessed 2 and 4 days after damage. Bone marrow cells mobilization was evaluated by the white blood cell count and the assessment of circulating clonogenic haematopoietic progenitors (colony forming unit-cells). Results In this experimental model, although granulocyte colony stimulating-factor induced the significant mobilization of colony forming unit-cells, the study cytokine had no effect on liver injury (serum alanine amino transaminase level and necrotic index) and liver regeneration (mitotic index and bromodeoxyuridine incorporation), regardless of the administration schedule. Conclusions This study does not support the conclusion that: (1) granulocyte colony stimulating-factor exerts a protective effect against toxic-induced, non-lethal acute liver injury and (2) promotes hepatocyte regeneration.

Published
2007

11. Malignant progression of a small HCC nodule: Hypovascular ‘early HCC’ converted to hypervascular ‘small HCC’ within six months

Author

Rita Golfieri, Franco Trevisani, F Fusco, S. Li Bassi, Mauro Bernardi, Paolo Caraceni, Francesca Coppola, Golfieri R, Coppola F, Fusco F, Li Bassi S, Caraceni P, Bernardi M, and Trevisani F.

Subjects
Adult, Pathology, medicine.medical_specialty, Carcinoma, Hepatocellular, Biopsy, Fine-Needle, Lesion, Humans, Medicine, Ultrasonography, Hepatitis, Hepatology, medicine.diagnostic_test, business.industry, Liver Neoplasms, Gastroenterology, Magnetic resonance imaging, Nodule (medicine), Hypervascularity, Hepatitis C, Chronic, medicine.disease, Magnetic Resonance Imaging, Early hcc, Hepatocellular carcinoma, Practice Guidelines as Topic, Female, Radiology, Malignant progression, medicine.symptom, business
Abstract

We report a case of hepatocellular carcinoma superimposed on chronic hepatitis C virus (HCV) hepatitis in which final diagnosis of hepatocellular carcinoma was delayed because there was no consensus on hypervascularity with two diagnostic methods at the time of presentation. A 3 cm lesion was initially observed as hypovascular at multidetector-row computed tomography. Conversely, two months later the lesion appeared hypervascular at contrast-ultrasonography and gadolinium-enhanced dynamic magnetic resonance, and hyperintense after superparamagnetic iron oxide-enhanced T2W studies. Only in the late follow-up it was definitively confirmed as hypervascular in the arterial phase of multidetector-row computed tomography. This case clearly highlights some pitfalls in the European Association for the study of the liver guidelines for hepatocellular carcinoma management, which were readdressed in the last American Association for the Study of Liver Diseases (AASLD) and in the forthcoming international proposals, leading to more pragmatic suggestions for clinical practice.

Published
2007

12. Management of malnutrition in patients with cirrhosis requires a personalized educational approach

Author

Paolo Caraceni, Silvia Boffelli, Maurizio Baldassarre, Ferdinando Giannone, Maurizio Biselli, Marco Domenicali, Mauro Bernardi, Maristella Laggetta, and P. De Pasquale

Subjects
Malnutrition, Educational approach, medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Gastroenterology, medicine, In patient, medicine.disease, business, Intensive care medicine
Published
2016

13. The TLR10 polymorphism rs4129009 is associated to poor 28-day survival in patients with cirrhosis and acute on chronic liver failure precipitated by bacterial infection

Author

V. Arroyo, Maurizio Baldassarre, Alexander L. Gerbes, Ferdinando Giannone, Pere Ginès, M. Pavesi, Paolo Angeli, Paolo Caraceni, E. Marasco, Mauro Bernardi, V. Mantovani, Rajiv Jalan, Marco Domenicali, and Richard Moreau

Subjects
medicine.medical_specialty, Cirrhosis, Calorie, Hepatology, business.industry, Gastroenterology, medicine.disease, Sodium intake, Liver disease, Internal medicine, Advanced disease, Medicine, Acute on chronic liver failure, In patient, medicine.symptom, business, Wasting
Abstract

s / Digestive and Liver Disease 48S (2016) e1–e17 e17 showed that 70% of patients has insufficient intake of calories and 40-60% inadequate water and sodium intake, despite the nutritional indications provided by the hepatologist. The weekly macronutrient intake was insufficient in 70-95% of cases, with the exception of sugar, which was excessive in 87% of cases including diabetic patients. Conclusions: The intake of total calories anddifferentmacronutrients is inadequate in 80-90% of outpatients with cirrhosis, due to both scarce adherence to the indications given by the hepatologist and low knowledge of nutritional facts. Muscle wasting is very often present even in less advanced disease. This highlights the need of a personalized nutritional approach, including educational and motivational aspects. http://dx.doi.org/10.1016/j.dld.2015.12.047

Published
2016

14. Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study

Author

Stefano Fagiuoli, Annalisa Tortora, Gianluca Svegliati-Baroni, Alida Andrealli, Irene Cacciola, Raffaele Cozzolongo, Maria Assunta Zocco, Francesco Salerno, M. Zappimbulso, M. Cavallin, F. De Leonardis, A. Marin, Chiara Elia, Sergio Neri, Paolo Caraceni, Fabio Salvatore Macaluso, A. Roncadori, Arianna Lanzi, F. Levantesi, Elga Neri, Giacomo Zaccherini, D. Maiorca, Gianfranco Elia, Lucia Cesarini, F. Fidone, S. Boccia, Filomena Morisco, Fabio Pugliese, Aldo Airoldi, Vincenzo Sangiovanni, Oliviero Riggio, Sara Massironi, L. Simone, R. De Marco, G. Magini, Pierluigi Toniutto, Manuel Tufoni, Salvatore Piano, A Alberti, Francesco Giuseppe Foschi, Chiara Pasquale, Giovanni Parrella, Giacomo Laffi, Paolo Angeli, Silvia Nardelli, Marco Marzioni, Alessandro Federico, G. Butera, Riccardo Guarisco, Mauro Bernardi, Carlo Alessandria, Antonio Mastroianni, and Roberto Giulio Romanelli

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Gastroenterology, medicine.disease, Interim analysis, Liver disease, Internal medicine, Cohort, Ascites, medicine, Etiology, Liver function, Stage (cooking), medicine.symptom, business
Abstract

s / Digestive and Liver Disease 47S (2015) e1–e18 e7 (months; 95% CI): CPT 0 62 (52.9–71.1), A 44 (41.6–46.4), B 22 (19.7–24.3), C 9 (6.6–11.3), p

Published
2015

16. Clinical and prognostic relevance of albumin dimers in patients with cirrhosis: A novel identified structural alteration of the molecule

Author

Ferdinando Giannone, Paolo Caraceni, Mauro Bernardi, Maurizio Baldassarre, Daniela Patrono, Maristella Laggetta, Carlo Bertucci, Marco Domenicali, and Marina Naldi

Subjects
First episode, medicine.medical_specialty, Cirrhosis, Multivariate analysis, Hepatology, business.industry, Incidence (epidemiology), Hazard ratio, Gastroenterology, medicine.disease, Internal medicine, Covariate, Immunology, Medicine, Decompensation, business, Prospective cohort study
Abstract

partly improved its performance, but this result requires further confirmation. Aim: To assess the reliability of MELD-Na scores to predict mortality and to identify other independent prognostic factors in patientswithHCV-relatedcirrhosis after thefirst episodeofdecompensation. Patients and methods: The study design is a multicenter prospective cohort that enrolled all consecutive patientswithHCVrelated cirrhosis at the time of first episode of decompensation (Bruno, 2013). In time-to-event analyses, the considered events of interest were death or OLT. Hepatocellular carcinoma (HCC) was considered as a competing event. A direct comparison of a model that includes only MELD-Na score as a covariate and a model that included decompensation characteristic was carried out, as well. To evaluate the incremental predictive information of new disease definition we used the likelihood ratio test (LRT). Results: Two hundreds and two subjects were included in this analysis. Approximately two thirds of patients were men and the mean agewas 60.9 years. The distribution of CTP classeswas: 19.4% inclassA,61.0% inclassB, and19.6% inclassC.Cumulative incidence of failure was 18.2% and 27.9% at 12 and at 18 months, respectively. Median MELD-Na of 13 was considered as reference in the computation of the hazard ratios. Multivariate analysis is shown in Table 1. The 18-months risks of failure predicted by model considering only MELD-Na (Model 1) and by model including also Hb and Age (Model 2) were compared between patients with and without eventa. The continuous net reclassification improvement (NRI) index was 42.6%. Conclusions: In the clinical setting of HCV-related cirrhosis, MELD-Na calculation, with the inclusion of Hb value and age at the time of first decompensation, enhances the value of mortality prediction, thus enabling a better patient allocation for OLT.

Published
2014

17. Ischemia modified albumin (IMA) for the diagnosis of bacterial infection in hospitalized patients with cirrhosis

Author

Mauro Bernardi, R. Motta, Maristella Laggetta, Lucia Napoli, Paolo Caraceni, Marco Domenicali, Ferdinando Giannone, Maurizio Baldassarre, and E. Beltrandi

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, Hospitalized patients, business.industry, Internal medicine, Ischemia-modified albumin, Gastroenterology, medicine, medicine.disease, Intensive care medicine, business
Published
2014

19. A novel experimental model of decompensated liver cirrhosis induced by CCl4 inhalation in mice

Author

Paolo Caraceni, Marco Domenicali, C. Nanni, Lucia Catani, Ferdinando Giannone, Roberto M. Lemoli, Maurizio Baldassarre, C. Quarta, Maria Martha Bernardi, and Giovanna Lucchetti

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, Inhalation, business.industry, Experimental model, Internal medicine, Gastroenterology, medicine, CCL4, medicine.disease, business
Published
2008

20. Acute gastrointestinal bleeding prolongs QT interval in cirrhosis

Author

Marco Domenicali, K. Fontana, Paolo Caraceni, Mauro Bernardi, Marta Frigerio, Andrea Zambruni, V. Santi, Federica Mirici-Cappa, R. Casadio, Giulia Magini, A. Di Micoli, E. Bracci, and Franco Trevisani

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, Acute gastrointestinal bleeding, business.industry, Internal medicine, Gastroenterology, medicine, medicine.disease, business, QT interval
Published
2008

24. OC-29 Terlipressin and albumin vs midodrine plus octreotide and albumin in the treatment of hepatorenal syndrome in patients with cirrhosis: results of a controlled clinical trial by A.I.S.F

Author

Angelo Gatta, M. Cavallin, Paolo Caraceni, Maria Martha Bernardi, F. Salinas, Massimo Cazzaniga, Pierluigi Toniutto, Lorenzo Ridola, Ezio Fornasiere, Silvano Fasolato, C. Colletta, Manuela Merli, Francesco Salerno, Paolo Angeli, and A. Di Giacomo

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Midodrine, Gastroenterology, Albumin, Octreotide, medicine.disease, Liver disease, surgical procedures, operative, Hepatorenal syndrome, Internal medicine, medicine, Liver function, Terlipressin, business, medicine.drug
Abstract

were treated with RFA (n=69), and the others underwent HR (n=63). The two groups were similar for liver disease status. The outcome was considered in terms of overall survival (OS) and disease-free survival (DFS) calculated by the Kaplan-Meier method. Differences among groups were validated by log-rank test. Results: The 1-, 3and 5-year OS rates for the RFA group and the HR group were 91%, 75%, 52%, and 97%, 92%, 74%, respectively. The corresponding DFS rates for the 2 groups were 64%, 28%, 5%, and 85%, 63%, 40%, respectively. OS and DFS were significantly lower in the RFA group than in the HR group (p=0.0210 and p=0.00001). The 5-year HCC recurrence rate was higher in the RFA group than in the HR group (87% vs. 60%; p = 0.0010). Conclusions: HR may provide better survival and lower recurrence rates than RFA for patients with VE HCC. HR should still be employed for those patients with a single small tumor and well-preserved liver function, as suggested by BCLC staging system. RFA should be chosen for patients with an unresectable single tumor for HCC position and grade of liver damage.

Published
2012

25. F-27 Endocannabinoids in advanced cirrhosis: have we picked the right one?

Author

Paolo Caraceni, Flaminia Fanelli, Ferdinando Giannone, Marco Mezzullo, Maurizio Baldassarre, C. Maggioli, Marco Domenicali, Maria Martha Bernardi, and I. Belluomo

Subjects
medicine.medical_specialty, Hepatology, business.industry, Advanced cirrhosis, Internal medicine, Gastroenterology, Medicine, business, Endocannabinoid system
Published
2012

26. Effect of β3-adrenoceptor agonist SR58611A on portal pressure of rats with compensated cirrhosis

Author

Maurizio Baldassarre, Marco Domenicali, Annalisa Berzigotti, Ferdinando Giannone, Valentina Vasina, R. la Torre, Mauro Bernardi, Marco Zoli, F. De Ponti, and Paolo Caraceni

Subjects
medicine.medical_specialty, Endocrinology, Cirrhosis, Hepatology, business.industry, Internal medicine, Portal venous pressure, Gastroenterology, medicine, medicine.disease, business, β3 adrenoceptor agonist
Published
2009

27. Endocannabinoids and endocannabinoid-related molecules in patients with liver cirrhosis

Author

Paolo Caraceni, G.L. Grazi, V. Di Marzo, Marco Domenicali, Rita Golfieri, F. Piscitelli, Mauro Bernardi, Ferdinando Giannone, S. Petrosino, Antonella Viola, Annalisa Berzigotti, Marco Zoli, Matteo Cescon, and Caraceni P, Domenicali M, Viola A, Piscitelli F, Petrosino S, Giannone F, Berzigotti A, Cescon M, Grazi G.L, Golfieri R, Zoli M, Di Marzo V, Bernardi M.

Subjects
Cirrhosis, Hepatology, business.industry, liver cirrhosis, Gastroenterology, Pharmacology, medicine.disease, Endocannabinoid system, endocannabinoid-related molecule, Medicine, lipids (amino acids, peptides, and proteins), In patient, business, Endocannabinoid
Abstract

Background/aim. Endogenous cannabinoids (ECs) include anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Recently, novel EC-related molecules have been discovered, i.e. oleoyl-ethanolamine (OEA) and palmitoyl-ethanolamine (PEA). AEA has been implicated in the pathogenesis of cardiovascular alterations in experimental cirrhosis, but the data in humans are sporadic and limited to AEA. Thus, we assessed whether: (1) the EC system is up-regulated in cirrhosis by comparing plasma and liver EC levels in cirrhotic pts and controls; (2) the cirrhotic liver contributes to the circulating EC by measuring their concentrations in brachial and hepatic veins; and (3) the EC levels correlate with systemic hemodynamics, portal pressure, liver and renal functions.

Published
2009

30. 16 Successful treatment of CCL4-induced acute liver failure with portal vein arterialization in the rat

Author

Paolo Caraceni, Mauro Bernardi, R. Bertelli, Roberto Montalti, M. Pariani, Paolo Beltempo, Antonino Cavallari, Lorenza Puviani, A. M. Pertosa, Pasquale Chieco, and Bruno Nardo

Subjects
medicine.medical_specialty, Hepatology, business.industry, Portal venous pressure, Internal medicine, Gastroenterology, Cardiology, medicine, Liver failure, Portal vein, CCL4, business
Published
2003

31. Effect of prostaglandin infusion and nutritional supplementation in rat fatty liver subjected to preservation injury

Author

Paolo Caraceni, A. M. Pertosa, Marco Domenicali, M. Bemardi, Elisabetta Maiolini, and Franco Trevisani

Subjects
medicine.medical_specialty, Hepatology, Nutritional Supplementation, business.industry, Fatty liver, Gastroenterology, Prostaglandin, medicine.disease, chemistry.chemical_compound, Endocrinology, chemistry, Internal medicine, Medicine, business
Published
2001

32. Mitochondrial injury in rat fatty liver exposed to cold preservation and reperfusion

Author

Marco Domenicali, Paolo Caraceni, Mauro Bernardi, Giorgio Lenaz, Cristina Bianchi, Elisabetta Maiolini, C. Tritto, A. M. Pertosa, Franco Trevisani, and G. Parenti Castelli

Subjects
medicine.medical_specialty, Endocrinology, Hepatology, business.industry, Internal medicine, Fatty liver, Gastroenterology, medicine, Cold preservation, business, medicine.disease
Published
2001

33. Oxidative damage in mitochondria isolated from rat fatty liver exposed to warm ischemia-reperfusion injury

Author

Paolo Caraceni, Emanuele Altomare, Gianluigi Vendemiale, Franco Trevisani, Ignazio Grattagliano, Marco Domenicali, and Mauro Bernardi

Subjects
medicine.medical_specialty, Hepatology, business.industry, Fatty liver, Gastroenterology, Mitochondrion, medicine.disease, Warm ischemia, Oxidative damage, Endocrinology, Internal medicine, medicine, business, Reperfusion injury
Published
2001

Catalog

Books, media, physical & digital resources
See catalog results